Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

M. R. Bristow, H. Krause-Steinrauf, R. Nuzzo, Cheng Seng Liang, J. Lindenfeld, Brian D Lowes, B. Hattler, W. T. Abraham, L. Olson, S. Krueger, S. Thaneemit-Chen, J. M. Hare, H. S. Loeb, M. J. Domanski, E. J. Eichhorn, R. Zelis, P. Lavori

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P<0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group- dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions-In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.

Original languageEnglish (US)
Pages (from-to)1437-1442
Number of pages6
JournalCirculation
Volume110
Issue number11
DOIs
StatePublished - Sep 14 2004

Fingerprint

Adrenergic Agents
Norepinephrine
Survival
Placebos
Heart Failure
Hospitalization
Sympatholytics
Adrenergic Antagonists
Mortality
Therapeutics
Multivariate Analysis
bucindolol

Keywords

  • Heart failure
  • Mortality
  • Nervous system, sympathetic
  • Risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial. / Bristow, M. R.; Krause-Steinrauf, H.; Nuzzo, R.; Liang, Cheng Seng; Lindenfeld, J.; Lowes, Brian D; Hattler, B.; Abraham, W. T.; Olson, L.; Krueger, S.; Thaneemit-Chen, S.; Hare, J. M.; Loeb, H. S.; Domanski, M. J.; Eichhorn, E. J.; Zelis, R.; Lavori, P.

In: Circulation, Vol. 110, No. 11, 14.09.2004, p. 1437-1442.

Research output: Contribution to journalArticle

Bristow, MR, Krause-Steinrauf, H, Nuzzo, R, Liang, CS, Lindenfeld, J, Lowes, BD, Hattler, B, Abraham, WT, Olson, L, Krueger, S, Thaneemit-Chen, S, Hare, JM, Loeb, HS, Domanski, MJ, Eichhorn, EJ, Zelis, R & Lavori, P 2004, 'Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial', Circulation, vol. 110, no. 11, pp. 1437-1442. https://doi.org/10.1161/01.CIR.0000141297.50027.A4
Bristow, M. R. ; Krause-Steinrauf, H. ; Nuzzo, R. ; Liang, Cheng Seng ; Lindenfeld, J. ; Lowes, Brian D ; Hattler, B. ; Abraham, W. T. ; Olson, L. ; Krueger, S. ; Thaneemit-Chen, S. ; Hare, J. M. ; Loeb, H. S. ; Domanski, M. J. ; Eichhorn, E. J. ; Zelis, R. ; Lavori, P. / Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial. In: Circulation. 2004 ; Vol. 110, No. 11. pp. 1437-1442.
@article{ce27cdd2c8ca41c881c082d4f6f83d79,
title = "Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial",
abstract = "Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P<0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group- dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18{\%} of the bucindolol group but only 1{\%} of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions-In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.",
keywords = "Heart failure, Mortality, Nervous system, sympathetic, Risk factors",
author = "Bristow, {M. R.} and H. Krause-Steinrauf and R. Nuzzo and Liang, {Cheng Seng} and J. Lindenfeld and Lowes, {Brian D} and B. Hattler and Abraham, {W. T.} and L. Olson and S. Krueger and S. Thaneemit-Chen and Hare, {J. M.} and Loeb, {H. S.} and Domanski, {M. J.} and Eichhorn, {E. J.} and R. Zelis and P. Lavori",
year = "2004",
month = "9",
day = "14",
doi = "10.1161/01.CIR.0000141297.50027.A4",
language = "English (US)",
volume = "110",
pages = "1437--1442",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-Blocker Evaluation of Survival Trial

AU - Bristow, M. R.

AU - Krause-Steinrauf, H.

AU - Nuzzo, R.

AU - Liang, Cheng Seng

AU - Lindenfeld, J.

AU - Lowes, Brian D

AU - Hattler, B.

AU - Abraham, W. T.

AU - Olson, L.

AU - Krueger, S.

AU - Thaneemit-Chen, S.

AU - Hare, J. M.

AU - Loeb, H. S.

AU - Domanski, M. J.

AU - Eichhorn, E. J.

AU - Zelis, R.

AU - Lavori, P.

PY - 2004/9/14

Y1 - 2004/9/14

N2 - Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P<0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group- dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions-In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.

AB - Background-Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. Methods and Results-Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the β-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the β-blocker/ sympatholytic agent bucindolol. Baseline norepinephrine level was associated with a progressive increase in rates of death or death plus CHF hospitalization that was independent of treatment group. On multivariate analysis, baseline norepinephrine was also a highly significant (P<0.001) independent predictor of death. In contrast, the relation of the change in norepinephrine at 3 months to subsequent clinical outcomes was complex and treatment group- dependent. In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase at 3 months was associated with increased subsequent risks of death or death plus CHF hospitalization. In the bucindolol-treated group but not in the placebo-treated group, the 1st quartile of marked norepinephrine reduction was associated with an increased mortality risk. A likelihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were at an increased risk for death related to marked reduction in norepinephrine at 3 months. Conclusions-In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result of sympatholysis, which compromised the efficacy of this third-generation β-blocker.

KW - Heart failure

KW - Mortality

KW - Nervous system, sympathetic

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=4544318680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544318680&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000141297.50027.A4

DO - 10.1161/01.CIR.0000141297.50027.A4

M3 - Article

VL - 110

SP - 1437

EP - 1442

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -